LGND
Price
$166.82
Change
-$0.92 (-0.55%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.25B
60 days until earnings call
SYRE
Price
$16.98
Change
-$0.01 (-0.06%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.03B
62 days until earnings call
Interact to see
Advertisement

LGND vs SYRE

Header iconLGND vs SYRE Comparison
Open Charts LGND vs SYREBanner chart's image
Ligand Pharmaceuticals
Price$166.82
Change-$0.92 (-0.55%)
Volume$500
Capitalization3.25B
Spyre Therapeutics
Price$16.98
Change-$0.01 (-0.06%)
Volume$3.6K
Capitalization1.03B
LGND vs SYRE Comparison Chart in %
Loading...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LGND vs. SYRE commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LGND is a Buy and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (LGND: $166.75 vs. SYRE: $17.00)
Brand notoriety: LGND and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LGND: 84% vs. SYRE: 67%
Market capitalization -- LGND: $3.25B vs. SYRE: $1.03B
LGND [@Biotechnology] is valued at $3.25B. SYRE’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LGND’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • LGND’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LGND’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 7 bullish TA indicator(s).

  • LGND’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than LGND.

Price Growth

LGND (@Biotechnology) experienced а +3.12% price change this week, while SYRE (@Biotechnology) price change was +3.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

LGND is expected to report earnings on Nov 05, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($3.25B) has a higher market cap than SYRE($1.03B). LGND has higher P/E ratio than SYRE: LGND (46.19) vs SYRE (1.72). LGND YTD gains are higher at: 55.623 vs. SYRE (-26.976). LGND has higher annual earnings (EBITDA): -45.94M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. LGND (255M). SYRE has less debt than LGND: SYRE (0) vs LGND (5.74M). LGND has higher revenues than SYRE: LGND (188M) vs SYRE (0).
LGNDSYRELGND / SYRE
Capitalization3.25B1.03B317%
EBITDA-45.94M-222.15M21%
Gain YTD55.623-26.976-206%
P/E Ratio46.191.722,692%
Revenue188M0-
Total Cash255M527M48%
Total Debt5.74M0-
FUNDAMENTALS RATINGS
LGND vs SYRE: Fundamental Ratings
LGND
SYRE
OUTLOOK RATING
1..100
2314
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
42100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
3762
P/E GROWTH RATING
1..100
9181
SEASONALITY SCORE
1..100
32n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (72) in the Pharmaceuticals Major industry is in the same range as LGND (73) in the Biotechnology industry. This means that SYRE’s stock grew similarly to LGND’s over the last 12 months.

LGND's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for SYRE (100) in the Pharmaceuticals Major industry. This means that LGND’s stock grew somewhat faster than SYRE’s over the last 12 months.

LGND's SMR Rating (94) in the Biotechnology industry is in the same range as SYRE (97) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to SYRE’s over the last 12 months.

LGND's Price Growth Rating (37) in the Biotechnology industry is in the same range as SYRE (62) in the Pharmaceuticals Major industry. This means that LGND’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as LGND (91) in the Biotechnology industry. This means that SYRE’s stock grew similarly to LGND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LGNDSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 22 days ago
74%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RLGYX11.36N/A
N/A
Russell Inv Global Equity Y
MSVZX9.79N/A
N/A
MassMutual Small Company Val I
NWJEX114.33N/A
N/A
Nationwide NYSE Arca Tech 100 Idx R6
CSJAX67.23N/A
N/A
Cohen & Steers Realty Shares A
SJGIX33.32N/A
N/A
Steward Large Cap Growth I